Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 21, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 910,000 ordinary shares of 25 pence each.
- Purchase Price: 1,374.66 pence per share.
- Treasury Holdings: 115,938,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,830,133,708 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on September 21, 2005. This action was taken under authority granted by shareholders at the Annual General Meeting on May 25, 2005. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 910,000 shares purchased at 1,374.66 pence per share.
- Confirm the updated total share count and Treasury holdings as of September 21, 2005.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share repurchase authority.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.